Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

SHINE collaborates with University of Wisconsin-Madison and WARF Therapeutics to create kidney and prostate cancer treatments

Press releases may be edited for formatting or style | October 21, 2024 Molecular Imaging


About SHINE:
Headquartered in Janesville, Wisconsin, SHINE Technologies is an industry leader in next-generation fusion, deploying innovative fusion and fusion-based technology that seamlessly combines safety, cost-efficiency, and environmental responsibility. SHINE's fusion expertise drives innovation across multiple sectors, from advanced radiation testing for aerospace and defense to medical isotope production for cancer treatments.

stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats

The company's groundbreaking fusion systems support critical applications in national security, scientific research, and industrial testing. Simultaneously, SHINE is pioneering solutions in healthcare, producing essential medical isotopes like lutetium-177 and soon, molybdenum-99 for diagnostic and therapeutic use.


About WARF:
Incorporated as a nonprofit foundation in 1925, WARF has a founding purpose "to promote, encourage, and aid scientific investigation and research at and within the University of Wisconsin-Madison." Over 98 years the foundation has funded more than $4.5 billion in cumulative research grants to UW-Madison and the Morgridge Institute for Research (adjusted for inflation), has been issued more than 4,200 patents (with 2,245 active patents), generates an additional 375 invention disclosures and 55 revenue-generating licenses each year, and has helped create 198 startup companies based on UW-Madison technologies. For more information, visit warf.org and watch a video about how WARF stewards the Cycle of Innovation.


About WARF Therapeutics:
Consistent with WARF's mission to support UW-Madison research and make a global impact, WARF Therapeutics is a major initiative to move new pharmaceuticals closer to the market and patients. The program will take select assets and lead them through preclinical development, towards commercialization and the benefit of human lives. More at warf.org/therapeutics.


About Advance Radiotheranostics (ART) Lab:
The Advanced Radiotheranostics Laboratory, led by Reinier Hernandez, PhD, is an academic lab dedicated to the discovery and development of novel radiopharmaceuticals for imaging and therapy. The lab also focuses on understanding the radiobiology of cancers to inform the development of more effective interventions to treat the most aggressive types of cancer.

Back to HCB News

You Must Be Logged In To Post A Comment